{"prompt": "['10.0', 'STATISTICAL CONSIDERATIONS', '10.1', 'Study Design/Endpoints', 'This is a prospective observational study to evaluate the quality of life of patients receiving', 'liposomal doxorubicin for HIV-associated Kaposi sarcoma and a single institution in', 'Tanzania. The exploratory aim of this trial is to assess clinical data collection quality for', 'site evaluation and training purposes only.', 'All patients presenting for care of HIV-associated KS at Bugando Medical Centre during', 'a 1-year study period will be approached for enrollment.', '10.2', 'Sample Size/Accrual Rate', 'We anticipate approximately 1-2 participant will be accrued each month, for a total of', 'approximately 12 to 20 participants.', '10.3', 'Statistical Analysis', 'We expect 1-2 participants per month during a 1-year enrollment for a total of 12-20', 'participants. With limited enrollment, statistics are exploratory only. QOL questionnaires', 'will be collected prior to treatment, after 3 cycles, at treatment completion and 3 months', 'after treatment completion. The four domains of the FACT-G questionnaire will be', 'determined for each questionnaire: physical well-being, social/family well-being,', 'emotional well-being and functional well-being. Using general estimating equations, we', 'will explore changes in these domains with time. Logistic regression analyses will be used', 'to correlate changes in quality of life domains with clinical response.', 'AMC-S007 (Version 2.0) 20MAR2018', '39', 'NCI Version Date 20MAR2018']['11.0', 'ROLE OF DATA MANAGEMENT', '11.1', 'CRF Instructions', 'Access to the internet data entry system for this study, Advantage eClinical, and', 'instructions for recording of study data on CRFs will be provided by the AMC ODMC at', 'www.amcoperations.com. Participating institutions are responsible for submitting data', 'and/or data forms via Advantage eClinical in accordance with the AMC Data Entry Guide', \"and specific form instructions, within the timelines specified by the AMC's Standards of\", 'Procedure for Site Performance Measures.', '11.2', 'Data Quality', 'It is the responsibility of the AMC ODMC to assure the quality of data for the study (See', 'Appendix III, AMC Data and Safety Monitoring Plan). This role extends from protocol', 'development to generation of the final study database.', '11.3', 'Data Monitoring', 'This study will be monitored in compliance with AMC policies and by the Clinical Data', 'Update System (CDUS) Version 3.0. Cumulative protocol- and participant-specific CDUS', 'data will be submitted electronically to CTEP on a quarterly basis. Reports are due January', '31, April 30, July 31, and October 31. Instructions for submitting data using the CDUS can', 'be found on the CTEP Web site (http://ctep.cancer.gov/reporting/cdus.html). The AMC', 'ODMC is responsible for compiling and submitting CDUS data to CTEP for all participants', 'and for providing the data to the Principal Investigator for review.', 'AMC-S007 (Version 2.0) 20MAR2018', '40', 'NCI Version Date 20MAR2018']['12.0', 'ETHICAL AND REGULATORY CONSIDERATIONS', '12.1', 'IRB Approval and Informed Consent', 'The principles of Institutional Review Board (IRB) approval and informed consent', 'described in the Department of Health and Human Services (DHHS) regulations for the', 'Protection of Human Subjects regulations (45 CFR Part 46) must be followed. IRB', 'approval of the protocol and the informed consent form must be given in writing.', \"The sponsor's designee (AMC ODMC) must receive a copy of the letter of approval from\", 'the IRB/IEC, which specifically approves the protocol and informed consent, before', 'participant enrollment. The IRB/IEC must also approve any significant changes to the', 'protocol and documentation of this approval must be sent to the AMC ODMC. The IRB', 'must review the research project at least once every 365 days during the duration of the', 'project. Continuing approval of the project must also be given in writing and provided to', 'the AMC ODMC.', 'Records of all study review and approval documents must be kept on file by the', 'Investigator and are participant to inspection during or after completion of the study. AEs', 'must be reported to the IRB according to local procedures. The IRB should receive', 'notification of completion of the study and final report within 3 months of study completion', 'and termination. The Investigator will maintain an accurate and complete record of all', 'submissions made to the IRB, including a list of all reports and documents submitted.', 'Written informed consent will be obtained from the participant. The nature, significance', 'and risks associated with the study must be explained to the participant. The informed', 'consent will describe the purpose of the study, the procedures to be followed, the risks and', 'benefits of participation, all risks of study participation as listed in the model informed', 'consent form, and all other elements of informed consent as required by regulation. A copy', 'of the consent form will be given to the participant to keep.', 'In', 'addition, any institution(s) conducting research according to the guidelines of this', 'protocol is required to adhere to local and national laws and regulations governing the', 'confidentiality and disclosure of health information.', '12.2', 'Changes to the Protocol', 'Any change or addition to this protocol requires a written protocol amendment that must', 'be approved by CTEP and the Investigator before implementation. All amendments require', 'approval by the IRB/IEC of the treating institution. A copy of the written approval of the', 'IRB/IEC and NIMR must be sent to the ODMC.', '12.3', 'Women and Minorities', 'This study is being conducted by the NCI-sponsored AIDS Malignancy Consortium', '(AMC). As part of their contractual obligations, each participating site within the AMC', 'and the AMC as a whole is required to assure that the participation of women and minority', 'participants reflects the percentage representation of these populations in their geographic', 'region. As such, it is expected that the representation of participants on this trial will reflect', 'the constitution of the respective populations.', 'AMC-S007 (Version 2.0) 20MAR2018', '41', 'NCI Version Date 20MAR2018']['Table 12-A: Accrual Targets', 'INTERNATIONAL PLANNED ENROLLMENT REPORT', 'Ethnic Categories', 'Racial Categories', 'Not Hispanic or Latino', 'Hispanic or Latino', 'Total', 'Female', 'Male', 'Female', 'Male', 'American Indian/', '0', '0', '0', '0', '0', 'Alaska Native', 'Asian', '0', '0', '0', '0', '0', 'Native Hawaiian or', 'Other', 'Pacific', '0', '0', '0', '0', '0', 'Islander', 'Black or African', '10', '10', '0', '0', '20', 'American', 'White', '0', '0', '0', '0', '0', 'More Than One', '0', '0', '0', '0', '0', 'Race', 'Total', '10', '10', '0', '0', '20', 'AMC-S007 (Version 2.0) 20MAR2018', '42', 'NCI Version Date 20MAR2018']", "completion": ""}